iX Biopharma Ltd. reported earnings results for the half year ended December 31, 2023. For the half year, the company reported sales was SGD 2.67 million compared to SGD 2.53 million a year ago. Net loss was SGD 7.33 million compared to SGD 7.35 million a year ago.

Basic loss per share from continuing operations was SGD 0.0096 compared to SGD 0.0096 a year ago. Diluted loss per share from continuing operations was SGD 0.0096 compared to SGD 0.0096 a year ago.